The cicada covid variant ba 3. 2 has been identified in Ontario and several other jurisdictions, but local health data and expert commentary suggest limited change for most people’s day-to-day care. First detected in South Africa and later in U. S. surveillance, the strain appears in wastewater in many states and in a modest number of clinical samples in Ontario. Public health tools show recent COVID-19 activity that rose through winter and has stabilized in the province.
Background and context
Public Health Ontario’s latest epidemiological survey shows 21 infections were identified in the province between Jan. 18 and Feb. 14. The variant was first identified on Nov. 22, 2024 in South Africa and later detected in the United States on June 27, 2025 through the Centers for Disease Control and Prevention’s traveller surveillance program. CDC data show the variant has been found in wastewater samples from 25 U. S. states and has been reported in at least 23 countries. Public Health Ontario’s online Respiratory Virus Tool indicates COVID-19 activity was lower in the province between March 15 and 21 versus the previous week, and that cases spiked from November to mid-January before levelling off.
Cicada Covid Variant Ba 3. 2: data, symptoms and diagnostics
Laboratory and surveillance findings imply the variant is circulating but not yet dominant in most sampled populations. CDC sampling in mid-March showed about 0. 55% of COVID-19 viruses sampled in the U. S. were the BA. 3. 2 variant. Clinically, the symptom profile remains overlapping with other respiratory illnesses — sniffles, cough, muscle aches and fever — and clinicians note that loss of taste and smell is no longer a hallmark. Local wastewater trends may hint at which viruses circulate in a community, but individual diagnosis still requires testing when symptoms arise.
Experts caution that genetic changes matter for immunity even when clinical presentation remains similar. The variant’s spike proteins carry mutations that raise concern for immune evasion from prior infection or booster shots, a point emphasized in recent public commentary on viral genetics.
Expert perspectives and practical implications
“The symptom range is still going to be the same, and the prevention is still going to be the same, ” said Dr. Isaac Bogoch, infectious disease specialist. He added that the virus is no longer novel for most people because many have prior infection or vaccination, and that current patterns are not overwhelming the health-care system as earlier waves did.
“There is not really a distinct trait between these respiratory illnesses, ” said Dr. Geeta Sood, epidemiologist at Johns Hopkins Bayview Medical Center, noting clinicians cannot reliably distinguish COVID-19 from influenza or RSV by symptoms alone. Marlene Wolfe, assistant professor of environmental health at Emory University, said community-level wastewater data and local surveillance are important because circulation can vary widely by location.
Jennifer Nuzzo, director of the Pandemic Center at Brown University School of Public Health, characterized current respiratory disease activity as relatively quiet compared with some previous seasons, but emphasized that place-specific patterns influence which viruses are more likely in a given community. Masking behaviors and uptake of the latest COVID-19 shots were also described as factors that shape transmission dynamics this season.
Regional and global impact, and what to watch next
At present the cicada covid variant ba 3. 2 has been detected in multiple continents and in widespread wastewater surveillance, yet routine clinical practice for diagnosis and treatment remains unchanged for most patients. The principal concerns now are whether the variant’s mutations will alter immunity at a population level and whether changes in circulation will lead to localized spikes in severe illness among older adults and immunocompromised people.
Public health authorities continue to use surveillance tools — clinical testing, wastewater monitoring and epidemiological surveys — to track trends. In Ontario, recent provincial data showing stabilized activity after a winter surge illustrate how regional trends can diverge from national or international patterns. Monitoring of sample proportions, clinical burden and hospital utilization will indicate whether BA. 3. 2 moves beyond its current footprint.
Given the available data and expert commentary, the immediate practical message is steady: testing when symptomatic, protecting high-risk individuals, and watching surveillance updates remain the most actionable steps. How health systems and communities respond if the variant’s prevalence rises further will be a test of surveillance sensitivity and targeted protection measures — and an open question for the months ahead: will BA. 3. 2 remain a minor player in circulation, or will it drive renewed localized waves that require renewed mitigation?
